News

The clinical trial will take place at four academic centers – University of California, the University of Minnesota, the University of Tennessee, and the University of Alabama. “Recent

All patients who complete the phase III clinical trial will be offered the opportunity to receive Alzhemed in the extension study, to be initiated in the second quarter

The patent issue follows an announcement of a notice of allowance in mid-January. The patent provides further coverage of cancer treatment using organic arsenic, including ZIO-101, in combination

The three trials each enrolled approximately 40 patients who have either undergone cholecystectomy, hernia repair or total knee replacement surgery. In all three trials, patients were randomized to

The initial project, bio-simulation of BioLineRx’s patented BL-1020 for the treatment of schizophrenia, will serve as a proof of concept using Optimata’s technology and provide a basis for

The compound, IT-101, is a combination of Insert’s patented polymer technology, Cyclosert, and the anticancer compound camptothecin. The application seeks to assess the formula in patients with unresectable

ISIS 301012, a second-generation antisense drug, inhibits apoB-100, a protein critical to the synthesis and transport of the “bad” cholesterol, low density lipoprotein cholesterol (LDL-C) and very low

The new worldwide licensing agreement expands a previous one, under which Oscient had rights to the drug in the US and Canada only. Oscient will now assume full

Transgenomic has granted NorDiag exclusive European commercial rights to use its proprietary Wave System and associated consumables to perform molecular diagnostic testing for the detection of colorectal and